PURE Stock Overview

Develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. More details

PURE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 14.8% per year over past 5 years

Does not have a meaningful market cap ($7M)

Negative shareholders equity

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

PURE Bioscience, Inc. Competitors

Titanium Holdings Group

OTCPK:TTHG

US$2.0m

CV Sciences

OTCPK:CVSI

US$6.2m

Integrated BioPharma

OTCPK:INBP

US$10.0m

Gold Flora

OTCPK:GRAM

US$7.2m

Price History & Performance

Summary of share price highs, lows and changes for PURE Bioscience
Historical stock prices
Current Share Price	US$0.065
52 Week High	US$0.16
52 Week Low	US$0.059
Beta	-0.0026
1 Month Change	1.56%
3 Month Change	-7.45%
1 Year Change	-55.17%
3 Year Change	-72.09%
5 Year Change	-77.59%
Change since IPO	-99.87%

Recent updates

Shareholder Returns

	PURE	US Household Products	US Market
7D	4.7%	-2.4%	-2.8%
1Y	-55.2%	10.6%	24.1%

Return vs Industry: PURE underperformed the US Household Products industry which returned 11.7% over the past year.

Return vs Market: PURE underperformed the US Market which returned 24.5% over the past year.

Price Volatility

Is PURE's price volatile compared to industry and market?
PURE volatility
PURE Average Weekly Movement	26.6%
Household Products Industry Average Movement	2.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	18.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: PURE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PURE's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1992	12	Robert Bartlett	www.purebio.com

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. Its technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. The company offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products.

PURE Bioscience, Inc. Fundamentals Summary

How do PURE Bioscience's earnings and revenue compare to its market cap?
PURE fundamental statistics
Market cap	US$7.14m
Earnings (TTM)	-US$3.30m
Revenue (TTM)	US$1.80m

4.0x

P/S Ratio

-2.2x

P/E Ratio

Is PURE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PURE income statement (TTM)
Revenue	US$1.80m
Cost of Revenue	US$762.00k
Gross Profit	US$1.04m
Other Expenses	US$4.34m
Earnings	-US$3.30m

Last Reported Earnings

Oct 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.03
Gross Margin	57.60%
Net Profit Margin	-183.86%
Debt/Equity Ratio	-100.4%

How did PURE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 06:59
End of Day Share Price	2025/01/02 00:00
Earnings	2024/10/31
Annual Earnings	2024/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PURE Bioscience, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Keith Markey	Griffin Securities
Guoqian Zeng	Zacks Investment Research Inc.